RxDoctor Payments DataLook up a doctor →

Evan Sehgal, MD

Interventional Cardiology · Hasbrouck Heights, NJNPI 1982671871

Payments from drug & device makers

$60,034in general payments, 2019–2025

Across 849 payments — averaging $70.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$50K
  • Medtronic$2K
  • Amgen$1K
  • Novartis$958
  • Boehringer Ingelheim$925
  • Amarin Pharma, Inc.$790
  • plus $4K from 24 others

What the payments were for

  • Speaking & faculty fees$38,23564%
  • Travel & lodging$8,76615%
  • Food & beverage$12,75421%
  • Education$2780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,034 in reported general payments places this provider in the 80th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$217,073
Medicare patients
625
Services billed
3,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis31$794,393
EliquisApixaban370$457,845
Repatha SureclickEvolocumab354$398,306
Praluent PenAlirocumab319$356,897
JardianceEmpagliflozin184$232,678
XareltoRivaroxaban128$158,033
FarxigaDapagliflozin Propanediol128$138,234
NexlizetBempedoic Acid/Ezetimibe111$98,753
EntrestoSacubitril/Valsartan32$42,022
VascepaIcosapent Ethyl42$34,286
VerquvoVericiguat18$23,968
Colchicine290$23,310
Rosuvastatin Calcium1,356$21,510
Ezetimibe695$19,528
Metoprolol Succinate982$17,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$447$1,252,238401 claims
Boehringer IngelheimJardiance$925$232,678184 claims
Johnson & JohnsonXarelto$305$158,033128 claims
AstraZenecaFarxiga$749$138,234128 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$49,913$114,375128 claims
NovartisEntresto$958$42,02232 claims
MerckVerquvo$288$23,96818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Hasbrouck Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →